Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Multicenter, open label, prospective study including successively a phase I trial and then a
phase II trial Phase I : Open label, non-randomized, sequential dose escalation of both
drugs, vinblastine and nilotinib.
Phase:
Phase 2
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Collaborator:
Innovative Therapies For Children with Cancer Consortium